Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023

Rhea-AI Summary

Rain Oncology Inc. (NasdaqGS: RAIN) announced it will report its fourth quarter and full-year financial results for 2022 on March 9, 2023. This will include highlights of recent progress, primarily focusing on its lead candidate, milademetan, an oral small molecule designed to inhibit the MDM2-p53 complex and reactivate p53. A conference call and webcast will be hosted at 2:00 pm PT (5:00 pm ET) to discuss these results. Interested parties can access the call via dial-in or the provided webcast link. Rain is committed to precision oncology, selecting patients based on genetic profiling to enhance therapeutic effectiveness.

Positive

• Upcoming financial results announcement on March 9, 2023.
• Focus on lead product milademetan, targeting a significant oncogenic pathway.
• Hosting a conference call to directly communicate financial and business highlights.

Negative

• None.

NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 and highlights of recent progress on Thursday, March 9, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.

Conference Call and Webcast Details:
Date: March 9, 2023
Time: 2:00 PT (5:00 pm ET)
Dial In Numbers: 1 (877) 704-4453 (U.S. Toll Free) / 1 (201) 389-0920 (International)

Conference ID: 13735982

Webcast Link: https://edge.media-server.com/mmc/p/pdg97w5e

Replay of the call will be available by visiting the "Events" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com

FAQ

When will Rain Oncology report its financial results for Q4 2022?

Rain Oncology will report its financial results on March 9, 2023.

What is milademetan in relation to Rain Oncology?

Milademetan is Rain Oncology's lead product candidate, a small molecule inhibitor targeting the MDM2-p53 complex.

What time is the Rain Oncology conference call on March 9, 2023?

The conference call will take place at 2:00 pm PT (5:00 pm ET).

How can I listen to the Rain Oncology conference call?

You can listen to the conference call by dialing the provided numbers or accessing the webcast link shared in the press release.